Robert W. Baird reaffirmed their hold rating on shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in a research report sent to investors on Monday. They currently have a $32.00 price target on the stock.
Several other analysts also recently commented on the company. Raymond James Financial, Inc. assumed coverage on Medpace Holdings in a research note on Friday, September 29th. They set a market perform rating on the stock. Zacks Investment Research raised Medpace Holdings from a hold rating to a strong-buy rating and set a $38.00 price objective on the stock in a research note on Saturday, September 9th. Finally, Jefferies Group LLC reaffirmed a hold rating and set a $31.00 price objective (up previously from $30.00) on shares of Medpace Holdings in a research note on Wednesday, August 2nd. Five investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Medpace Holdings currently has an average rating of Buy and a consensus target price of $34.20.
Shares of Medpace Holdings (NASDAQ:MEDP) opened at 34.07 on Monday. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of 59.98 and a beta of -0.86. The stock’s 50 day moving average price is $32.21 and its 200-day moving average price is $29.50. Medpace Holdings has a 12 month low of $21.76 and a 12 month high of $38.94.
Medpace Holdings (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.08. The business had revenue of $94.60 million for the quarter, compared to the consensus estimate of $92.71 million. Medpace Holdings had a return on equity of 9.32% and a net margin of 5.37%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. On average, equities research analysts predict that Medpace Holdings will post $1.43 EPS for the current fiscal year.
WARNING: “Medpace Holdings’ (MEDP) “Hold” Rating Reiterated at Robert W. Baird” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/10/12/medpace-holdings-medp-hold-rating-reiterated-at-robert-w-baird.html.
In related news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $30.27, for a total transaction of $60,540,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 25.80% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new stake in shares of Medpace Holdings in the 1st quarter valued at about $145,000. Tudor Investment Corp ET AL raised its stake in shares of Medpace Holdings by 16.4% in the 1st quarter. Tudor Investment Corp ET AL now owns 6,864 shares of the company’s stock valued at $205,000 after purchasing an additional 967 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Medpace Holdings in the 2nd quarter valued at about $220,000. Credit Suisse AG acquired a new stake in shares of Medpace Holdings in the 1st quarter valued at about $231,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Medpace Holdings in the 1st quarter valued at about $246,000. 15.98% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Holdings Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.